Compare STKS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STKS | VERU |
|---|---|---|
| Founded | 2004 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.8M | 41.9M |
| IPO Year | 2011 | 1996 |
| Metric | STKS | VERU |
|---|---|---|
| Price | $1.09 | $2.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $4.25 | ★ $25.67 |
| AVG Volume (30 Days) | 33.6K | ★ 145.2K |
| Earning Date | 11-04-2026 | 12-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $805,722,000.00 | $16,296,958.00 |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | $7.92 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 19.66 | N/A |
| 52 Week Low | $0.97 | $2.04 |
| 52 Week High | $2.65 | $7.33 |
| Indicator | STKS | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 40.24 |
| Support Level | $1.07 | N/A |
| Resistance Level | $1.99 | $2.68 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 40.43 | 18.18 |
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.